In Brief: McNeil's Nasalcrom
Executive Summary
McNeil's Nasalcrom: Rx-to-OTC switch will be considered by the pulmonary-allergy panel in conjunction with the Nonprescription Drugs Advisory Committee at 8:30 a.m. on Oct. 10 at the Holiday Inn-Bethesda. On Oct. 11, the committee will consider an Rx-to-OTC switch for Schering-Plough's Vancenase AQ, also at 8:30 in Bethesda...